| Reference number |
2026-02239 |
| Coordinator |
Thioredoxin Systems AB |
| Funding from Vinnova |
SEK 4 881 979 |
| Project duration |
October 2026 - April 2029
|
| Status |
Ongoing |
| Venture |
Eurostars |
Purpose and goal
The project aims to develop new antibacterial drug candidates that inhibit bacterial thioredoxin reductase (TrxR), with a focus on multidrug-resistant urinary tract infections. By combining drug development with analysis of real patient data, the project will identify and further develop promising compounds and strengthen the conditions for future clinical studies.
Expected effects and result
The project is expected to result in at least one promising antibacterial drug candidate with documented preclinical efficacy and safety profile, as well as a data-driven platform that supports the development and planning of clinical studies. In the longer term, the results may contribute to new treatment options against antibiotic-resistant infections, more efficient drug development and strengthened European innovative capacity.
Planned approach and implementation
The project is being implemented by the Swedish TXN Systems and the Portuguese MTG. TXN develops and optimizes TrxR inhibitory substances through screening, chemical development and preclinical studies of efficacy and tolerability. MTG analyzes patient and resistance data and develops data-driven tools for patient stratification and study design. The results are integrated to guide drug development and future clinical studies.
The project description has been provided by the project members themselves and the text has not been looked at by our editors.